# TRAINING UPDATE

Lab Location: Department: SGMC Core Lab 
 Date Distributed:
 7/5/2017

 Due Date:
 7/25/2017

 Implementation:
 7/25/2017

# **DESCRIPTION OF PROCEDURE REVISION**

Name of procedure:

# Prealbumin by Dimension Vista® System SGAH.C911 v1

**Description of change(s):** 

Section	Reason
3.2	Remove specimen onboard stability, change refrigerated sample stability to match PI
4,5,6	Remove individual section labeling instructions and add general one
10.5	Move patient review from section 6
15	Update to new standard wording
17	Update PI dates

This revised SOP will be implemented on July 25, 2017

Document your compliance with this training update by taking the quiz in the MTS system.

Technical	SOP
-----------	-----

Title	Prealbumin by Dimension Vista® System		
Prepared by	Ashkan Chini	Date:	4/16/2015
Owner	Robert SanLuis	Date:	4/16/2015

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
Refer to the electronic signature		
page for approval and approval		
dates.		

Review		
Print Name	Signature	Date

# **TABLE OF CONTENTS**

1.	Test Information	2
2.	Analytical Principle	3
3.	Specimen Requirements	3
4.	Reagents	4
5.	Calibrators/Standards	4
6.	Quality Control	6
7.	Equipment And Supplies	8
8.	Procedure	8
9.	Calculations	10
10.	Reporting Results And Repeat Criteria	10
11.	Expected Values	11
12.	Clinical Significance	11
13.	Procedure Notes	11
14.	Limitations Of Method	12
15.	Safety	12
16.	Related Documents	12
17.	References	12
18.	Revision History	13
19.	Addenda	13

# 1. TEST INFORMATION

Assay	Method/Instrument	Local Code
Prealbumin	Dimension Vista® System	PRALB

# Synonyms/Abbreviations

Thyroxine-binding prealbumin, TBPA, Transthyretin

# Department

Chemistry

# 2. ANALYTICAL PRINCIPLE

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# **3.** SPECIMEN REQUIREMENTS

### **3.1** Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

# 3.2 Specimen Type & Handling

Criteria		
Type -Preferred	Plasma (Lithium Heparin)	
-Other Acceptable	Serum	
<b>Collection Container</b>	Plasma: Mint green top tube (PST)	
	Serum: Red top tube, Serum separator tube (SST)	
Volume - Optimum	1.0 mL	
- Minimum	0.5 mL	
<b>Transport Container and</b>	Collection container or Plastic vial at room temperature	
Temperature		
Stability & Storage	Room Temperature: 8 hours*	
Requirements	Refrigerated: 24 hours* 7 days	
	Frozen: 7 days*	
Timing Considerations	Serum or plasma should be physically separated from cells	
	as soon as possible with a maximum limit of two hours	
	from the time of collection.	
Unacceptable Specimens	Specimens that are unlabeled, improperly labeled, or those	
& Actions to Take	that do not meet the stated criteria are unacceptable.	
	Request a recollection and credit the test with the	
	appropriate LIS English text code for "test not performed"	
	message. Examples: Quantity not sufficient-QNS; Wrong	

Form revised 2/02/2007

Criteria	
	collection-UNAC. Document the request for recollection in
	the LIS.
<b>Compromising Physical</b>	Gross hemolysis. Reject sample and request a recollection.
Characteristics	Credit the test with the appropriate LIS English text code
	explanation of HMT (Specimen markedly hemolyzed)
	Lipemic or turbid samples, which cannot be clarified by
	centrifugation, must not be used. Samples should be free
	of fibrin and other particulate matter.
Other Considerations	Allow Red Top or SST to clot completely prior to
	centrifugation.

\*This information does not match Siemens Package Insert. It is based on the validation which is performed internally in this laboratory. Validation information is available for review.

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

#### 4. **REAGENTS**

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

#### 4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Prealbumin	Siemens, Flex® reagent cartridge, Cat. No. K7064

#### 4.2 Reagent Preparation and Storage

Reagent	Prealbumin
Container	Reagent Cartridge
Storage	Store at 2 - 8° C
Stability	<ul> <li>Stable until expiration date stamped on reagent cartridges.</li> <li>Sealed wells on the instrument are stable for 90 days.</li> <li>Once wells 1 - 12 have been entered by the instrument, they are stable for 21 days.</li> </ul>
Preparation	All reagents are liquid and ready to use.

#### 5. CALIBRATORS/STANDARDS

### 5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
PROT1 CAL	Siemens Dimension Vista®, Cat. No. KC710U

### 5.2 Calibrator Preparation and Storage

Calibrator	PROT1 CAL	
Preparation	Calibrator is ready for use. No preparation is required. Invert	
	gently to mix. Avoid vigorous shaking and foam formation.	
Storage/Stability	• Store at 2-8° C	
	• <b>Unopened calibrator</b> is stable until expiration date stamped on the box.	
	• <b>Opened Calibrator:</b> once the stopper of the vial is	
	punctured, assigned values are stable for 9 days when stored	
	on board the Dimension Vista System.	

### 5.3 Calibration Parameter

Criteria	Special Notations	
<b>Reference Material</b>	PROT1 CAL	
Assay Range	3-60  mg/dL	
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in mg/dL	
Frequency	<ul> <li>Every new reagent cartridge lot.</li> <li>Every 30 days for any one lot</li> <li>When major maintenance is performed on the analyzer.</li> <li>When control data indicates a significant shift in assay.</li> </ul>	
Calibration Scheme	6 Levels, n = 3	

#### 5.4 Calibration Procedure

#### **Auto Calibration:**

- 1. Place the required calibrator vials in a carrier. Make sure the barcode labels are entirely visible through the slots.
- 2. Place the carrier in the loading area.
- 3. Position the carrier with the labels facing away from the user.
- 4. Press the **Load** button.
- 5. Automatic calibration requires that calibrators be on the instrument. As the time for processing approaches, the instrument reviews onboard inventory for the appropriate calibrators.

# Manual Calibration:

1. Verify that calibrators and reagents are in inventory on the instrument.

- 2. Press System > Method Summary > Calibration.
- 3. Select a method from the sidebar menu. Press the **Order Calibration** button on the screen.
- 4. Verify that the information on the screen is correct. Verify that the calibrator lot is correct using the drop-down menu.
  - a. When calibrating using Vials press OK.
  - b. When calibrating using Cups, check the Use Cups box. This displays the rack and cup position fields. For additional cups use the positions in ascending order. Be sure to use the number of calibration levels and cups as specified in the method IFU. Scan the rack barcode and place calibrator cups in an adapter in position 1 on a rack. Press **OK** and load the rack on the instrument.
- 5. The status field in the calibration screen changes sequentially to Awaiting Scheduling, Preparing Calibrators and Processing.

### 5.5 Tolerance Limits

IF	THEN
If result fall within assay-specific specification,	proceed with analysis
and QC values are within acceptable limits,	
If result falls outside assay-specific specification,	troubleshoot the assay and/or
or QC values are out of Acceptable limits,	instrument and repeat calibration

# 6. QUALITY CONTROL

#### 6.1 Controls Used

Controls	Supplier and Catalog Number
Liquichek Immunology Control	Bio-Rad Laboratories
Levels 1, 2 and 3	Cat. No. 594, 595 and 596

#### 6.2 Control Preparation and Storage

Control	Immunology Control Levels 1, 2 and 3	
Preparation	Allow the vial to stand at room temperature (18-25°C) until it is completely thawed. Before sampling, gently swirl the vial several times to ensure homogeneity. After each use, promptly replace the stopper and return to 2-8°C storage.	
Storage/Stability	Once the control is thawed, all analytes will be stable for 30 days at 2 to 8°C. Unthawed controls are stable until the expiration date at -20 to $-70^{\circ}$ C.	

#### 6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Dimension Vista® QC Schedule in the Laboratory policy Quality Control Program and in the Dimension Vista® Quick Reference Guide.

# 6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action	
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.	
2	<ul> <li>Run Rejection Criteria</li> <li>Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported.</li> <li>The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.</li> </ul>	
3	<ul> <li>Corrective Action:</li> <li>All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed</u> according to the Laboratory QC Program. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program.</li> </ul>	
	• Corrective action documentation must follow the Laboratory Quality Control Program.	
4	Review of QC	
	• QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee.	
	• If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.	

# 6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.

• Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

# 6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

# 7. EQUIPMENT and SUPPLIES

#### 7.1 Assay Platform

Dimension Vista® System

# 7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

#### 7.3 Supplies

- Aliquot Plates
- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

# 8. **PROCEDURE**

Prealbumin Flex<sup>®</sup> reagent cartridge Cat. No. K7064 is required to perform this test.

Prealbumin is performed on the Dimension Vista<sup>®</sup> System after the method is calibrated (see Reference Material in Calibration section) and Quality Controls are acceptable.

**NOTE:** For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Sample Processing
1.	A sample rack holding tubes or cups is placed on the rack input lane.
2.	The sample shuttle moves the rack to the barcode reader which identifies the rack and samples to the system.
3.	The rack moves into the sample server and to the rack positioner.
4.	At the same time, aliquot plates move from the aliquot loader into position.
5.	The aliquot probe aspirates the sample from the tubes or cups and dispenses it into the wells of the aliquot plates.
6.	After each aspirate-dispense action, the probe is thoroughly rinsed inside and out to prevent sample carryover.
7.	When sample aspiration is completed, the sample server moves the rack back to the sample shuttle, where it is placed on the output lane and can be removed by the operator
7.	When sample aspiration is completed, the sample server moves the rack b

8.2	Specimen Testing
1.	For QC placement and frequency, refer to the Dimension Vista <sup>®</sup> QC Schedule in the Laboratory QC Program.
2.	Follow the instructions, outlined in the Dimension Vista <sup>®</sup> Operator's Manual
3.	The instrument reporting system contains error messages to warn the user of specific malfunctions. Results followed by such error messages should be held for follow-up. Refer to the Dimension Vista <sup>®</sup> system manual "Error messages" section for troubleshooting.
4.	Follow protocol in Section 10.5 "Repeat criteria and resulting" for samples with results above or below the Analytical Measurement Range (AMR). Investigate any failed delta result and repeat, if necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

Test Conditions		
Initial Sample Dilution:	1:5	
Diluted Sample Dilution:	26.9 μL	
Diluted Volume:	102.2 μL	
Chase Volume:	15 μL	
Antiserum to human Prealbumin	21.5 µL	
Test Temperature:	37° C	
Reaction Time:	6 minutes	
Wavelength:	840 nm	
Type of measurement:	Nephelometric	

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

### 9. CALCULATIONS

The instrument automatically calculates the concentration of Prealbumin in mg/dL.

# 10. REPORTING RESULTS AND REPEAT CRITERIA

#### **10.1** Interpretation of Data

None required

#### 10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

#### **10.3** Units of Measure

mg/dL

#### **10.4** Clinically Reportable Range (CRR)

3-60 mg/dL

#### **10.5** Review Patient Data

Each result is reviewed for error messages. Refer to the Dimension Vista system manual "Error messages" section for troubleshooting. Resolve any problems noted before issuing patient reports.

#### **10.6** Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall within the AMR or CRR may be reported without repeat. Values that fall outside these ranges must be repeated.

IF the result is	THEN
< 3 mg/dL	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as:
< 5 mg/uL	< 3 mg/dL
> 60 mg/dL	Report as: > 60 mg/dL

Form revised 2/02/2007

Message	Code
Verified by repeat analysis	Append –REP to the result.

# **11. EXPECTED VALUES**

#### **11.1 Reference Ranges**

20-40 mg/dL

# 11.2 Critical Values

None established

### 11.3 Standard Required Messages

None established

# 12. CLINICAL SIGNIFICANCE

Prealbumin is synthesized in the liver and acts as a binding protein for thyroxin and retinolbinding protein. The serum concentration reflects the synthesis capacity of the liver and is markedly diminished in malnutrition and other conditions. Due to the short half life of approximately two days, prealbumin may be suitable for monitoring the nutritional status and efficacy of parenteral nutrition.

# **13. PROCEDURE NOTES**

- **FDA Status:** FDA Approved/modified
- Validated Test Modifications: Specimen stabilities have been modified from the package insert based on in-house stability studies performed at Shady Grove Medical Center.

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up. Refer to your Dimension Vista Operator's Guide.

The expected maximum observed standard deviations for repeatability using n = 5 replicates at the following Prealbumin concentrations are:

Prealbumin Concentration	Acceptable S.D. Maximum		
18.5 mg/dL	2.8 mg/dL		
36.3 mg/dL	7.8 mg/dL		

#### 14. LIMITATIONS OF METHOD

#### 14.1 **Analytical Measurement Range (AMR)**

3-60 mg/dL

#### 14.2 Precision

	Mean	Standard Deviation (%CV)	
Material	mg/dL	Repeatability	Within-Lab
PROT1 Control			
PROT1 CON L	20.4	0.7	0.7
PROT1 CON M	33.8	1.4	1.4
PROT1 CON H	46.1	1.9	1.9

#### 14.3 **Interfering Substances**

#### **HIL Interference:**

The Prealbumin method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias, defined as the difference between the control sample (does not contain interferent) and the test sample (contains interferent), is shown in the table below. Bias exceeding 10% is considered "interference".

Substance tested	Substance Concentration	Prealbumin mg/dL	Bias %
Hemoglobin (hemolysate)	1000	25	-4
Bilirubin (unconjugated)	60	26	1
Bilirubin (conjugated)	60	26	4

#### 14.4 **Clinical Sensitivity/Specificity/Predictive Values**

Not available

#### 15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

#### **RELATED DOCUMENTS** 16.

- Dimension Vista<sup>®</sup> Clinical Chemistry System Operator's Manual
   Dimension Vista<sup>®</sup> Calibration/Verification Procedure
   Dimension Vista<sup>®</sup> Cal Accept Guidelines

- 4. Dimension Vista<sup>®</sup> Calibration summary
- 5. Dimension Vista® Sample Processing, Startup and Maintenance procedure
- 6. Laboratory Quality Control Program

- 7. QC Schedule for Siemens Dimension Vista<sup>®</sup>
- 8. Laboratory Safety Manual
- 9. Safety Data Sheets (SDS)
- 10. Dimension Vista<sup>®</sup> Limits Chart (AG.F200)
- 11. Quest Diagnostics Records Management Procedure
- 12. Dimension Vista<sup>®</sup> System Error Messages Chart
- 13. Centrifuge Use, Maintenance and Functions Checks (Lab policy)
- 14. Hemolysis, Icteria and Lipemia Interference (Lab policy)
- 15. Repeat Testing Requirement (Lab policy)
- 16. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business\_Groups/Medical/qc/docs/qc\_bpt\_tea.xls
- 17. Current package insert Prealbumin Flex® Reagent Cartridge K7064

### **17. REFERENCES**

- 1. Package Insert, Prealbumin Flex<sup>®</sup> Reagent Cartridge K7064, Siemens Healthcare Diagnostics Inc., 06/2012.
- 2. Package Insert, PROT1 CAL, Siemens Healthcare Diagnostics Inc., 06/2014.
- 3. Package Insert, Immunology Control, Bio-Rad Laboratories, revised 4/2016.
- 4. Prealbumin by Siemens BNII SOP from Quest Diagnostics Nichols Institute in Chantilly, VA. Document CHA QDPC710 v3.1

#### **18. REVISION HISTORY**

Version	Date	Section	Reason	Reviser	Approval
0	6/12/17	3.2	Remove specimen onboard stability, change refrig. stability to match PI	L Barrett	R SanLuis
0	6/12/17		Remove individual section labeling instructions and add general one	L Barrett	R SanLuis
0	6/12/17	10.5	Move patient review from section 6	L Barrett	R SanLuis
0	6/12/17	15	Update to new standard wording	L Barrett	R SanLuis
0	6/12/17	17	Update PI dates	L Barrett	R SanLuis

#### **19. ADDENDA**

None